Pembrolizumab plus radiation for resected mucosal melanoma
Treatments studied
Part of Cancer, Ear, nose & throat clinical trials.
This trial studies whether giving pembrolizumab (an immunotherapy) together with a targeted form of radiation can help after surgery for mucosal melanoma. It aims to lower the chance of the cancer coming back and improve outcomes in people whose tumor was removed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have mucosal melanoma confirmed by tissue or cell testing, and it was removed with surgery.
- You must not have had radiation in the same treatment area before.
- You’re age 16 or older, and you’re well enough to do daily activities (performance status 0–2).
- Your blood counts and organ tests (kidneys, liver) need to be within allowed ranges.
- If you can become pregnant (or you’re a man who could have a partner who can become pregnant), you must use reliable birth control during the study and for 6 months after the last dose.
- You can sign consent and understand the study plan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether two medications, lenvatinib (a targeted therapy) and pembrolizumab (an immunotherapy), given before and after surgery, can help reduce the chance of mucosal melanoma coming back. If you are eligible, you would receive these drugs in addition to your standard surgery.
This Phase 2 trial tests giving radiation and immunotherapy before surgery for mucosal melanoma in the nose/sinuses or rectum. It may help shrink the tumor and improve outcomes while aiming to control the disease locally and in nearby areas.
This trial tests a combination of chemo drugs (paclitaxel polymersomes, carboplatin) and an immunotherapy (adebelimab) before surgery for people with mucosal melanoma that can be removed. The goal is to see if this treatment shrinks the tumor and improves outcomes.
This trial tests whether giving pembrolizumab (an immunotherapy medicine) together with short-course radiation before surgery helps people with localized rectal cancer. It is mainly for tumors that are microsatellite stable (MSS).
This trial tests a combination of three drugs (pucotenlimab, lenvatinib, and temozolomide) given before surgery for head and neck mucosal melanoma. The goal is to see if this therapy can shrink the tumor and improve outcomes.
This trial tests whether pembrolizumab (an immunotherapy drug) works better than the usual chemo plus radiation after surgery for cancer that has come back in the head and neck area. It may help reduce cancer returning or spreading by using your immune system, but eligibility depends on how the cancer came back and your prior treatments.
Hear when a new Mucosal Melanoma of the Head and Neck trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.